Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against... 
More about the company
Latest news on CEL-SCI CORPORATION
02/27 CEL SCI : NEW STORY CEL-SCI Announces That the NYSE MKT Approves Plan
02/27 CEL SCI : Announces That the NYSE MKT Approves Plan
02/22 CEL-SCI CORPORATION (NYSEMKT : CVM) Files An 8-K Entry into a Material Definitiv..
02/21 CEL SCI CORP : Entry into a Material Definitive Agreement, Unregistered Sale of ..
02/21 CEL SCI : Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vac..
02/17 CEL SCI : NEW STORY CEL-SCI Announces $1.0 Million Registered Direct Offering
02/17 CEL SCI : Announces $1.0 Million Registered Direct Offering
02/16 CEL-SCI CORPORATION : Reports First Quarter Fiscal 2017 Financial Results
02/16 CEL SCI : Research Reports Initiation on Biotech Stocks -- Heat Biologics, PDL B..
02/13 CEL SCI CORP : Other Events (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Geert R. Kersten CEO, CFO, Treasurer, Director & CAO
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION20
AMGEN, INC.19.39%129 711
CELGENE CORPORATION2.14%94 741
GILEAD SCIENCES, INC.-2.33%92 881
REGENERON PHARMACEUTIC..-1.66%39 573
ACTELION LTD22.36%28 883
More Results